Singapore-based ASLAN Pharmaceuticals has notched a first in its efforts to develop immunotherapies and targeted agents for Asia-prevalent tumor types under a refined cost model, roping in South Korea's Hyundai Pharmaceutical in a development and license deal of ASLAN001 for the treatment of a form of bile duct cancer, cholangiocarcinoma.
South Korea-based Hanmi Pharmaceutical has signed a deal with French pharma giant Sanofi to license its GLP-1 diabetes treatments as Sanofi attempts to revive its diabetes division, according to a report by Reuters.
Sanofi, stockpiling diabetes assets with eyes on Novo Nordisk and Eli Lilly, inked a deal worth up to $1.7 billion to bring in a late-stage treatment for the disease, partnering up with Lexicon Pharmaceuticals.
Sanofi signed a deal worth up to $4.2 billion to get its hands on a trio of diabetes treatments from South Korean drugmaker Hanmi Pharmaceutical, filling out its pipeline as it contends with rivals Novo Nordisk and Eli Lilly.
CRO Accelovance is pairing up with a nonprofit clinical research outfit to bring its services to the developing world.
Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.
Allergan expanded its pipeline with a $50 million deal to bring in a late-stage treatment for dry eye as the company works to reaffirm its commitment to R&D in the face of industrywide scrutiny.
Sanofi is pairing up with Germany's BioNTech in a collaboration potentially worth $1.5 billion, licensing some early-stage cancer immunotherapies that use messenger RNA to target tumors.
Shanghai-based WuXi PharmaTech has opened a door for Gilead Sciences in China that comes as the California-based maker of blockbuster hepatitis C drugs Sovaldi and Harvoni looks to expand in Asia, and particularly in China, for its leading therapies.
Suzhou-based MabSpace Biosciences has raised $15 million in Series A funding from Lilly Asia Ventures to develop the biotech's technology for antibodies that break the tolerance of the immune system.